NCT06308939View on ClinicalTrials.gov

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Eribulin

1.4mg/m\^2 day1、8，repeated every 3 week.

DRUG

Sintilimab

500mg once every three weeks.

Trial Locations (1)

310000

zhejiangCH, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT06308939 - Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | Biotech Hunter | Biotech Hunter